Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes Treating the Wrong Surrogate End Point?

被引：14

作者：

Goodarzi, Mark O. ^{[5
,6
]}

Psaty, Bruce M. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA

[2] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA

[3] Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA

[4] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA

[5] Cedars Sinai Med Ctr, Div Endocrinol Diabet & Metab, Inst Med Genet, Los Angeles, CA 90048 USA

[6] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2008年 / 300卷 / 17期

关键词：

D O I：

10.1001/jama.2008.510

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2051 / 2053

页数：3

共 15 条

[1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].

Abraira, C ;

Colwell, J ;

Nuttall, F ;

Sawin, CT ;

Henderson, W ;

Comstock, JP ;

Emanuele, NV ;

Levin, SR ;

Pacold, I ;

Lee, HS ;

Silbert, CK ;

Cxypoliski, R ;

Vasquez, M ;

Kernan, D ;

Niewoehner, C ;

Backes, M ;

Bradley, M ;

Crow, R ;

Rubino, F ;

Bushnell, D ;

Pfeifer, M ;

Service, FJ ;

Howard, B ;

Chew, E ;

Hoogwerf, B ;

Seigel, D ;

Clark, CM ;

Olefsky, JM ;

Porte, D ;

Sussman, KE ;

Johnson, N ;

Christine, B ;

Tir, K ;

Sather, M ;

Day, P ;

Morgan, N ;

Deykin, D ;

Gold, J ;

Huang, P .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188

[2]

Dandona P, 2004, METAB SYNDR RELAT D, V2, P137, DOI 10.1089/met.2004.2.137

[3] Hyperinsulinemia as an independent risk factor for ischemic heart disease [J].

Despres, JP ;

Lamarche, B ;

Mauriege, P ;

Cantin, B ;

Dagenais, GR ;

Moorjani, S ;

Lupien, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15) :952-957

[4] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[5]

Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743

[6] Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells [J].

Goalstone, ML ;

Natarajan, R ;

Standley, PR ;

Walsh, MF ;

Leitner, JW ;

Carel, K ;

Scott, S ;

Nadler, J ;

Sowers, JR ;

Draznin, B .

ENDOCRINOLOGY, 1998, 139 (10) :4067-4072

[7] Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease - The San Antonio Heart Study [J].

Hanley, AJG ;

Williams, K ;

Stern, MP ;

Haffner, SM .

DIABETES CARE, 2002, 25 (07) :1177-1184

[8]

HOLMAN RR, 10 YEAR FOLLOW UP IN

[9] The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort [J].

Kronmal, RA ;

Barzilay, JI ;

Tracy, RP ;

Savage, PJ ;

Orchard, TJ ;

Burke, GL .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2852-2858

[10] Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J].

Nathan, DM ;

Cleary, PA ;

Backlund, JYC ;

Genuth, SM ;

Lachin, JM ;

Orchard, TJ ;

Raskin, P ;

Zinman, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2643-2653

← 1 2 →